More evidence for JAK inhibitor in refractory RA
A hotly anticipated oral biologic improved a range of patient-reported outcomes in patients with severe disease who had failed multiple biologics.
Baricitinib, a selective JAK1 and 2 inhibitor, is currently being trialled in a number of phase 3 studies and was filed with the FDA earlier this year. Approval is expected later this year or in early 2017.
The current study looked at patient-reported outcomes from the RA-BEACON trial